| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.06 | 17.8% | 45.2% |
| Total Income | 1.06 | 17.8% | 45.2% |
| Expenditure | 4.01 | 13.6% | 22.3% |
| PBT | — | ||
| Net Profit | -2.86 | 6.7% | 12.6% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.80 | 36.2% | 309.1% |
Intelligent Bio Solutions Reports Q3 2026 Revenue Growth of 46% YoY
14 May 2026 · 14 May, 3:41 pm
Summary
Intelligent Bio Solutions Inc. announced its financial results for the fiscal third quarter and nine months ended March 31, 2026. The company reported a 46% increase in revenue for the third quarter, driven by a 59% increase in cartridge revenue. Nine-month revenue reached $3.07 million, up 39% year-over-year. The gross profit margin improved to 50.5% for the quarter and 49.3% for the nine-month period, reflecting operational efficiencies and increased sales volumes. Management believes the company is well-positioned to deliver continued growth through the remainder of fiscal 2026 and beyond.
Key Highlights
- 1
Intelligent Bio Solutions reported a 46% year-over-year increase in fiscal third-quarter revenue.
- 2
Cartridge revenue increased by 59% year-over-year, representing 66% of the quarterly sales.
- 3
Nine-month revenue reached $3.07 million, reflecting a 39% increase year-over-year.
- 4
The gross profit margin expanded to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month period.
- 5
Cartridge sales for the nine months ended March 31, 2026, were $1.86 million, up 46% year-over-year.
- 6
Reader sales for the nine months ended March 31, 2026, increased by 29% year-over-year to $672,839.
- 7
Cash and cash equivalents totaled $6.86 million as of March 31, 2026, compared to $740,371 at December 31, 2025.
Management Comments
Harry Simeonidis
“The third quarter marked another period of strong commercial execution and revenue growth. Cartridge revenue increased 59% year-over-year and accounted for 66% of Q3 revenue, confirming that customer utilization patterns align with our recurring revenue, razor-razorblade business model. Nine-month revenue of $3.07 million reflects consistent and compounding growth, and the business is continuing to strengthen ahead of important FDA regulatory milestones and our anticipated entry into the multi-billion-dollar U.S. market.”
Spiro Sakiris
“Our results this quarter and over the past nine months demonstrate that we are delivering on our core business fundamentals. Q3 gross margin was over 50%, up from 47% a year ago. This growth was driven by operational efficiencies and increased sales volumes. Our value-driven pricing structure has also remained consistent, as customers recognize the efficiency and cost-effectiveness of our fingerprint drug screening technology compared to traditional methods. Our nine-month marketing investment of $1.77 million has been a direct contributor to our 39% revenue growth and successful capital raising of $14.67 million (net of issuance costs), and we are now seeing improved marketing efficiency in Q3, with the quarter’s spend down 42% year-over-year while commercial momentum continues to accelerate.”
Informational and educational content only. Not investment advice.